Cytek Biosciences
CTKB | NASDAQ
$5.63
-$0.21 (-3.60%)
At close: Nov 16, 2026, 4:00 PM ET
$5.79
+$0.16 (+2.84%)
After-hours:
Nov 16, 2026, 7:10 PM ET
-3.60%
(1D)No price chart data available for 1D timeframe.
Rating
33
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #712/1021 (Top 70%)
Key Statistics
Market Data
Market Cap $736.31M
1D Range
5.59 5.83
52W Range
3.36 6.30
Valuation (TTM)
PE -8.94
PB 2.29
EV/EBITDA -17.07
Valuation (NTM)
Forward PE N/A
Forward PEG -0.07
Price Target $5.50
Cash Flow
FCF Yield -1.8%
SBC Adj. FCF Yield -4.6%
SBC Impact -152.6%
Margins
Gross Margin 54.8%
Operating Margin -21.1%
FCF Margin -6.5%
Growth (CAGR)
Revenue 3Y | 5Y 4.3% |
11.7%
Dil EPS 3Y | 5Y -102.7% |
-66.0%
FCF 3Y | 5Y -679.3% |
31.1%
Returns
ROA -18.2%
ROE -24.7%
ROIC -11.8%
Financial Health
Net Cash
$247.45M
Current Ratio 4.46
Interest Coverage -28.72
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary ...
Sector Healthcare
Industry Medical - Devices
Employees 682
IPO Date Jul 23, 2021
Website cytekbio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 4, 2026
EPS
-$0.05
Beat +28.57%
YoY:
-400.00% REV
$53.23M
Beat +0.34%
YoY:
+1.79%Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$5.50
Downside
-2.31%
Buy (2)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CTKB